The approval is based on a multi-center, randomized, open-label, controlled, Phase 3 KL166-III-06 study that evaluates the efficacy and safety profile of trastuzumab botidotin versus T-DM1 in patients ...
Two mainland biotech firms win global attention as Roche and Dianthus sign major licensing pacts, highlighting China’s growing role in next-generation drug development.
Enhertu Benefit in HER2-Low Breast Cancer That's Also HR-Negative Supported by Longer Follow-Up Data
Like with HR-positive patients, researchers found that patients with HR-negative or ER-low tumors lived longer on Enhertu than chemo after nearly three years.
NEW YORK – Akari Therapeutics on Wednesday said it hopes to raise $2.5 million by selling 3,125,000 American depositary shares (ADS) in a registered direct offering.
Adcytherix Raises EUR 105M Series A to Accelerate Breakthrough Antibody-Drug Conjugate Pipeline with Strategic Focus on Novel Payloads Financing ...
Of course, the Nintendo Switch 2 Pro Controller is going to feel great in-game. It should do for nearly $100. There's one ...
After charting several related moves earlier this year, Boehringer Ingelheim is returning to the antibody-drug conjugate well ...
Boehringer Ingelheim, which has so far inked at least five hefty partnerships—including its latest one with South Korea’s ...
The AirPods Pro 3 have two more hours battery life than the AirPods Pro 2 at eight hours, there are more ear tips so it is ...
As Tubulis prepares to unveil the first in-human data on its next-generation antibody drug conjugate (ADC) later this month, ...
The 21-valent pneumococcal conjugate vaccine V116 is well tolerated in adults living with HIV and induces immunity to all 21 ...
Explore a potential trade with CytomX (CTMX) stock as Q1’26 clinical data approaches for its EpCAM-targeting therapy. Read ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback